Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GPCR with free AI briefings, catalyst countdowns, and dilution alerts.

GPCR · Structure Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.2B Cash on Hand
33.5mo Cash Runway
Follow GPCR by email Get an email when GPCR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GPCR, unsubscribe in one click. Privacy

📣 What GPCR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Aleniglipron Obesity Phase 3 · NCT07654361 Recruiting
ACCG-2671 Obesity Phase 1/2 · NCT07815678 Recruiting
GSBR-1290 Overweight or Obesity Phase 1/2 · NCT05762471 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GPCR holds $1.2B in cash and short-term investments (as of Sep 30, 2026) and burns about $110.9M/quarter from operations, an estimated runway of 33.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 2 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GPCR files for a raise →

👥 Who Owns GPCR

Insiders 17.5% Institutions (267 holders) 82.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC
10% owner · +16,086 options
Insider 32,089,434 14.94% 2026-09-30
Wellington Management Group LLP Institution (13G, 5%+) 29,288,943 13.64% 2026-09-30
Deep Track Capital, LP Institution (13G, 5%+) 15,000,000 6.98% 2026-09-30
Jun Yoon
CHIEF FINANCIAL OFFICER · +128,892 options
Insider 2,956,242 1.38% 2026-03-19
Raymond C Stevens
CHIEF EXECUTIVE OFFICER, Director · +326,230 options
Insider 2,956,179 1.38% 2026-03-19
Crespo Blas Coll
CHIEF MEDICAL OFFICER · +95,141 options
Insider 258,228 0.12% 2026-09-18
Xichen Lin
CHIEF SCIENTIFIC OFFICER · +178,784 options
Insider 228,960 0.11% 2026-09-01
Matthew Lang
COO & GC · +223,776 options
Insider 184,614 0.09% 2026-04-15
Ashley Hall
Chief Development Officer · +59,535 options
Insider 155,187 0.07% 2026-03-19
John Joseph Berrios
Chief Commercial Officer · +174,612 options
Insider 140,766 0.07% 2026-08-06
Yingli Ma
CHIEF TECHNOLOGY OFFICER · +40,278 options
Insider 139,917 0.07% 2026-03-19

Share count 214,771,065 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GPCR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GPCR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.